Caris Life Sciences (CAI) Total Current Liabilities (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Total Current Liabilities of $143.9 million for Q1 2026, up 13.17% quarter-over-quarter from $127.1 million in Q4 2025.
Caris Life Sciences (CAI) Total Current Liabilities (2024 - 2026) Analysis & Trends
Caris Life Sciences' Total Current Liabilities history runs 3 years deep, the most recent figure standing at $143.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $143.9 million; the TTM figure through Mar 2026 stood at $143.9 million (changed N/A YoY), while the FY2025 annual figure was $127.1 million, down 23.14% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $143.9 million, up from $127.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $165.4 million in Q4 2024, with the low at $86.0 million in Q3 2025.
- The 3-year median for Total Current Liabilities is $127.1 million (2025), against an average of $122.5 million.
- Peak annual rise in Total Current Liabilities reached 23.14% in 2025, while the deepest fall reached 23.14% in 2025.
- Caris Life Sciences' Total Current Liabilities stood at $165.4 million in 2024, then retreated by 23.14% to $127.1 million in 2025, then gained by 13.17% to $143.9 million in 2026.
- Business Quant data shows CAI's Total Current Liabilities at $143.9 million in Q1 2026, $127.1 million in Q4 2025, and $86.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 191.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191.44 Mn |
| Mar 31, 2026 | 143.90 Mn |
| Dec 31, 2025 | 127.15 Mn |
| Sep 30, 2025 | 86.03 Mn |
| Jun 30, 2025 | 90.18 Mn |
| Dec 31, 2024 | 165.42 Mn |